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Strongyloides Stercoralis Infection in a Patient
with AIDS
Abhik Roy, MD, Gregory Young, MD, Geoffrey Koff, MD, and Tasha Kouvatsos, MD

Case
A 46-year-old male with a past medical history significant for
acquired immune deficiency syndrome (AIDS) presented with
constant, non-radiating epigastric pain, nausea, non-bloody
emesis, weakness, and lethargy. He had emigrated from
Honduras twenty years prior. The patient denied fever, chills,
recent travel, animal exposures, or sick contacts. His medications
included efavirenz/emtricitabine/tenofovir, valganciclovir,
trimethoprim/sulfamethoxazole, fluconazole, and iron.
Initial physical examination revealed a thin, lethargic male in
moderate discomfort, who was afebrile, tachycardic, tachypneic,
and hypotensive. The remainder of the examination showed
diffuse pulmonary crackles and epigastric tenderness. Labs
revealed bandemia and anemia. Urinalysis indicated a urinary
tract infection (UTI) and antibiotics were started. The initial
assessment was dehydration secondary to vomiting and UTI.
Given the patient’s persistent hypotension, he was transferred to
the medical intensive care unit with concern for sepsis. Volume
resuscitation with normal saline and packed red blood cells was
initiated. A computed tomography (CT) scan of the abdomen
showed small bowel obstruction (SBO) and enterocolitis. After
resuscitation, the patient was hemodynamically stable.
Shortly thereafter, the patient again developed hypotension and
hypoxic respiratory failure, ultimately requiring intubation. A
chest radiograph (CXR) revealed bilateral pulmonary edema,
with subsequent chest CT demonstrating worsening alveolar
infiltrates. A new rash was observed on the patient’s abdomen.
He was started empirically on steroids and pentamidine for
possible Pneumocystis jiroveci pneumonia. A bronchoscopy
was performed and demonstrated diffuse alveolar hemorrhage
of unknown etiology. Microbiology results from bronchoscopy
revealed Klebsiella pneumoniae and Strongyloides stercoralis.
Silver stain, acid fast bacilli, and Legionella were negative.
Steroids were immediately discontinued. Re-examination of
prior colonic biopsies obtained on previous admission a few
weeks prior revealed overlooked evidence of Strongyloides
infection.
After the diagnosis of Strongyloides hyperinfection, the patient
was started on oral ivermectin. Rectal ivermectin was started
one day later secondary to SBO. Both routes of administration
were continued for fourteen days. The patient’s respiratory
status gradually improved, but tracheostomy was required
for prolonged intubation. His SBO resolved and tube feeds
were started. He was transferred to a general medicine floor.
Repeat CT of the chest showed marked improvement of diffuse
alveolar infiltrates, and abdominal CT demonstrated resolving
enterocolitis. CXR eight days after completing ivermectin was
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normal. The patient did eventually expire from overwhelming
underlying illness

Strongyloidiasis – Epidemiology and Diagnosis
Strongyloides stercoralis is an intestinal nematode parasite that
is most commonly found in tropical and subtropical regions
world wide, with 30-100 million people infected around the
globe.1 As our case illustrates, many cases in the United States
are diagnosed in individuals who have previously been in other
endemic areas of the world.2-3
Infection with S. stercoralis begins when infectious larval forms
contact with human skin. Since S. stercoralis is most commonly
found in the soil and other infected fecal material, walking
barefoot in endemic areas is considered a significant risk factor.
The larvae penetrate the skin, enter the blood stream, travel
hematogenously to the lungs, and are ultimately swallowed into
the gastrointestinal tract where they mature into adult worms
and reproduce. Larvae can be passed in feces or re-enter the
blood stream to cause infection.3
Given this unique life-cycle, the diagnosis of S. stercoralis
infection is made by detecting larvae in stool or other bodily
fluids – including sputum and bronchoalveolar lavage fluid. 2-3

Clinical Manifestations
The clinical manifestations of S. stercoralis vary depending on
the stage of the infection and the host’s immune response. Up to
50% of infected patients, particularly those with intact immune
systems, remain asymptomatic.4
During the acute phase of infection (3-4 weeks after infestation),
most symptomatic patients present with cutaneous, gastrointestinal, and pulmonary complaints – all of which were seen in
our patient. At the site of larval penetration, localized reactions
occur – inflammation, pruritis, petechiae, and urticarial tracts.4,5
As the larvae migrate through the lungs, pulmonary symptoms
such as dry cough, wheezing, and dyspnea occur. Finally, as the
larvae settle in the gastrointestinal tract, patients experience
diarrhea and abdominal pain.6
Chronic strongyloidiasis results from the parasite’s ability
to perpetuate the infectious cycle through the process of
autoinfection. In symptomatic patients, chronic strongyloidiasis affects the same organ systems as in the acute phase, with
symptoms waxing and waning over years. Chronic infection
also produces the pathognomonic cutaneous finding of strongyloidiasis: larva currens – a transient, urticarial serpiginous
eruption involving the buttocks, thighs, and lower extremities.3,4
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Hyperinfection Syndrome and Disseminated
Strongyloidiasis
In hosts with fully functional immune systems, the rate of S.
stercoralis autoinfection is controlled over time, and the overall
parasitic burden remains low. Contrarily, immunocompromised
hosts lack the balance between excretion and maturation of
larvae within the gastrointestinal tract leading to higher rates of
autoinfection and total worm burden, which results in hyperinfection syndrome.3,4
During hyperinfection, increased parasite burden leads to the
exacerbation of gastrointestinal and pulmonary symptoms.
Reported complications of hyperinfection include intestinal
obstruction (as seen in our patient), paralytic ileus, intestinal
bleeding, hemoptysis, diffuse pulmonary hemorrhages, lung
abscesses, and respiratory compromise (also seen in our
patient).4,7 Invasion of organs such as the liver, heart, and kidney
have also been reported – the so called “disseminated strongyloidiasis”.3,4 Secondary infections are also common with hyperinfection as a result of the compromised intestinal barrier. Patients
with hyperinfection often have gram negative bacteremia, and
persistent bacteremia may lead to systemic complications
including meningitis, peritonitis, and endocarditis.3

Treatment and Prognosis
All patients diagnosed with strongyloidiasis require treatment.
The drug of choice for the treatment of uncomplicated strongyloidiasis is ivermectin – given as 200 ug/kg once daily for 1-2
days and then repeated in 2-3 weeks to ensure eradication.
Second line treatment is albendazole.8

intestinal, and pulmonary symptoms – particularly in immunocompromised patients who have been in endemic tropical
and subtropical regions of the world. Although immunocompetent patients with strongyloides infection often remain
asymptomatic, the immunocompromised may present with
disseminated and hyperinfection syndromes. Strongyloidiasis
is diagnosed by the detection of larvae in stool or other bodily
fluids. The first line treatment is a short course of oral ivermectin
for patients with uncomplicated disease or a prolonged course
for those with disseminated or hyperinfection syndromes.
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For patients with hyperinfection or disseminated disease, oral
ivermectin remains the treatment of choice with daily administration until clinical symptoms resolve and stool tests are
persistently negative.8
As demonstrated in our patient, those with hyperinfection may
not tolerate oral therapy, either because of severe infection or
poor bioavailability of oral medications secondary to gastrointestinal complications. In such cases, alternative salvage
therapies are often required including rectal and subcutaneous
administration of medications.8 In our case, rectal ivermectin
was used secondary to small bowel obstruction.
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The prognosis for patients with strongyloidiasis depends on the
severity of infection. Cure rates in patients with uncomplicated
strongyloidiasis have been reported to be as high as 97%.
Mortality is significantly higher, however, in patients who
develop hyperinfection and disseminated strongyloidiasis –
nearly 77 to 87%.9

Summary
As this case illustrates, strongyloidiasis should be suspected in
patients with the appropriate constellation of cutaneous, gastro-
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